4 innovative pharmaceutical companies completed financing of more than 100 million yuan to promote the research and development of new drugs

Recently, four Chinese innovative pharmaceutical companies announced that they have completed financing of more than 100 million yuan to promote the research and development of innovative double-antibody and polyclonal drugs, and the research and development of AI+RNA drugs
.
What are the highlights of these pharmaceutical companies? Take a look! Yinnuo Pharmaceutical completes US$120 million financing On December 23, Yinnuo Pharmaceutical announced the completion of a new round of financing of US$120 million
.
This round of financing was led by Youshan Capital and Huachuang Capital.
CICC Capital's CICC Qi Tak Fund, V Star Capital (V Star Capital), Langmafeng Venture Capital, Deyi Capital, Everbright Holdings, Xiaochi Capital , Guoke Jiahe, Pudong Investment Holdings followed the investment, the old shareholder Lanting Capital, Tongchuangweiye continued to raise the bet
.
This round of financing will be used for Suparutide's global Phase III clinical trials, the promotion of multiple First-in-Class pipeline products, and the construction of cGMP production bases
.
Yinnuo Pharmaceutical was established in 2015, dedicated to the research and development and industrialization of biological drugs for diabetes and metabolic diseases, and has a strong core management team
.
Takata Biotech has completed more than 100 million yuan of Series B financing.
On December 23, Takata Biotech announced that it has completed more than 100 million yuan of Series B financing
.
This round of financing was led by Morning One Investment, Tiger Pharmaceuticals participated in the pharmaceutical industry fund Taikun Fund, and multiple investors including Hangjin Investment, Haihui Investment and Minsheng Medicine participated
.
The funds raised in this round of financing will be used to advance the clinical progress of the Takata Tumor pipeline and the clinical registration application of the company's mRNA-LNP project
.
According to data, Takata Bio was established in 2013 and is an innovative drug R&D and production company focusing on lipid drugs
.
The company’s self-research pipeline covers small molecules, antibodies and gene therapy drugs, and has established an integrated platform to support the research and development of new lipid drugs, including preclinical evaluation, process development, translational research, clinical development and production, and it also has complete control LNP formulation research and development, production and quality control system
.
Xinhe Biotechnology completes 500 million yuan A+ round of financing On December 21, Xinhe Biotech announced the completion of 500 million yuan A+ round of financing
.
This round of financing was jointly led by PICC Capital and Zhou Yahui, and the Shunxi Fund, Jiayin Fund, CDH Investment and old shareholders under the State Management Center continued to invest in the field of RNA innovative drugs
.
This round of financing will be used to promote the research and development of new tumor antigen vaccines, tumor microenvironment immunomodulators, viral vaccines and other research pipelines of Xinhe Bio based on mRNA technology
.
At the same time, continue to optimize the artificial intelligence platform, improve the construction of RNA drug research and development and production bases, and accelerate the clinical and commercialization of innovative tumor drugs
.
According to data, Xinhe Biotechnology was established in 2017 and features AI-enabled RNA drugs
.
A multi-omics big data collection platform and a multi-bioomics database have been built, using AI and bio-information technology for in-depth drug target mining and fully automated drug design for innovative RNA drug research
.
Qiyu Biotechnology completed nearly 200 million yuan in Series B financing.
Recently, Qiyu Biotechnology completed nearly 200 million yuan in Series B financing.
This round of financing was led by Bank of Communications International (Bank of Communications Investment Fund), Guoshun Investment, Yuanhe Holdings , Lihe Hongxin, Tianfu Sanjiang Capital, Pudong Science and Technology and Longmen Capital participated in the investment
.
Qiyu Biotech stated that it will continue to focus on using its own technology platform to develop innovative biopharmaceuticals, and develop innovative biopharmaceuticals for intractable cancers and autoimmune diseases in China and the world, so as to benefit patients and meet the current unsatisfactory clinical needs.
Demand
.
According to data, Qiyu Biologics is an innovative macromolecular biopharmaceutical developer, whose goal is to develop new therapeutic drugs for the treatment of intractable cancer and autoimmune diseases in China and the world to benefit patients
.